Precision Plant Molecules (PPM) coined the term Cannamimetics to describe naturally inspired ways to access important, bioactive “minor” cannabinoids that currently manifest in existing hemp cultivars in de minimis concentrations. More effective plant-based extracts and concentrates can be formulated with these cannabinoids.
Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.
Opiant Pharmaceuticals Inc., a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced an exclusive global licensing agreement with Sanofi for the development and commercialization of drinabant for the treatment of acute cannabinoid overdose (ACO).
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
INSYS Therapeutics Inc. announced today that the company reached an agreement in principle with the Department of Justice to settle the DOJ’s civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.
GW Pharmaceuticals plc announced that the U.S. FDA accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for Epidiolex (cannabidiol or CBD) as an investigational treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
